Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients

被引：2

作者：

Ferrucci, Silvia ^{[1
]}

Tavecchio, Simona ^{[1
]}

Maronese, Carlo Alberto ^{[1
,2
]}

Balato, Anna

Di Brizzi, Eugenia Veronica ^{[3
]}

Ortoncelli, Michela ^{[4
]}

Ribero, Simone ^{[4
]}

Girolomoni, Giampiero ^{[5
]}

Maurelli, Martina ^{[5
]}

Fortina, Anna Belloni ^{[6
]}

Caroppo, Francesca ^{[6
]}

Naldi, Luigi ^{[7
,8
]}

Pezzolo, Elena ^{[8
]}

Nettis, Eustachio ^{[9
]}

Pugliese, Francesco ^{[9
]}

Stingeni, Luca ^{[10
]}

Hansel, Katharina ^{[10
]}

Rubegni, Giovanni ^{[11
]}

Calabrese, Laura ^{[12
]}

Russo, Filomena ^{[13
]}

Gola, Massimo ^{[14
]}

Magnaterra, Elisabetta ^{[14
]}

Rongioletti, Franco ^{[15
]}

Mercuri, Santo Raffaele ^{[15
]}

Paolino, Giovanni ^{[15
]}

Savoia, Paola ^{[16
,17
]}

Veronese, Federica ^{[17
]}

Foti, Caterina ^{[18
]}

Ambrogio, Francesca ^{[19
]}

Scalvenzi, Massimiliano ^{[20
]}

Napolitano, Maddalena

Patruno, Cataldo ^{[21
]}

Dastoli, Stefano ^{[21
]}

Corazza, Monica ^{[22
]}

Borghi, Alessandro ^{[22
]}

Calzavara-Pinton, Pier Giacomo ^{[23
]}

Rossi, Mariateresa ^{[23
]}

Offidani, Annamaria ^{[24
]}

Radi, Giulia ^{[24
]}

Bonzano, Laura ^{[25
]}

Ferreli, Caterina ^{[26
]}

Piras, Viviana ^{[26
]}

Satta, Rosanna ^{[27
]}

Sucato, Federica ^{[27
]}

Malagoli, Piergiorgio ^{[28
]}

Gaiani, Francesca ^{[28
]}

Micali, Giuseppe ^{[29
]}

Musumeci, Maria Letizia ^{[29
]}

Fargnoli, Maria Concetta ^{[30
]}

Esposito, Maria ^{[31
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[3] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy

[4] Univ Turin, Med Sci Dept, Dermatol Clin, Turin, Italy

[5] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

[6] Univ Padua, Dept Women & Children Hlth, Padua, Italy

[7] Italian Grp Epidemiol Res Dermatol, Study Ctr, Bergamo, Italy

[8] San Bortolo Hosp Vicenza, Dept Dermatol, Vicenza, Italy

[9] Univ Bari, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy

[10] Univ Perugia, Dept Med, Sect Dermatol, Perugia, Italy

[11] Univ Siena, Dept Ophthalmol, Siena, Italy

[12] Univ Siena, Dept Med Sci Surg & Neurosci, Sect Dermatol, Siena, Italy

[13] IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy

[14] Azienda Sanit & Univ Florence, Piero Palagi Hosp, Sect Dermatol, Viale Michelangiolo, Florence, Italy

[15] IRCCS San Raffaele Hosp, Dermatol Clin, Milan, Italy

[16] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy

[17] AOU Maggiore della Carita Novara, Novara, Italy

[18] Univ Bari, Dept Dermatol, Dipartimento Sci Biomed & Oncol Umana, Bari, Puglia, Italy

[19] Univ Bari, Dept Precis & Regenerat Med & Ionian Area DiMePRe, Sect Dermatol & Venereol, Bari, Italy

[20] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[21] Magna Graecia Univ Catanzaro, Catanzaro, Calabria, Italy

[22] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Emilia Romagna, Italy

[23] Univ Brescia, Dermatol Dept, Brescia, Italy

[24] Univ Politecn Marche, Dept Clin & Surg Specialties, Fac Med & Chirurg, Ancona, Marche, Italy

[25] AUSL Modena, Allergol Serv, Modena, Italy

[26] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

[27] Univ Sassari, Dept Med Surg & Expt Sci, Dermatol Unit, Sassari, Italy

[28] Ist Policlin San Donato, Milan, Italy

[29] Univ Catania, Catania, Italy

[30] Univ Aquila, Dept Dermatol, Laquila, Italy

[31] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[32] Univ Rome Sapienza, Dermatol Unit, Rome, Italy

[33] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 12期

关键词：

EUROPEAN GUIDELINES; ADULTS; MANAGEMENT; PLACEBO;

D O I：

10.1093/ced/llae208

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions. Objectives To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria [defined as the simultaneous achievement of a 90% reduction in Eczema Area and Severity Index score, itch-numeric rating scale (NRS) score <= 1, sleep-NRS score <= 1 and Dermatology Life Quality Index <= 1] were investigated. Results In total, 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506/2309 (21.9%), 769/1959 (39.3%), 628/1247 (50.4%), 330/596 (55.4%) and 58/106 (54.7%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AEs) were mild and were observed in 373/2364 (15.8%), 166/2066 (8.0%), 83/1291 (6.4%), 27/601 (4.5%) and 5/110 (4.5%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AEs led to treatment discontinuation in < 1% of patients during the evaluated time periods. Conclusions The high long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate-to-severe AD, regardless of clinical phenotype and course (persisting or relapsing) at baseline. Further research will be needed to investigate the effect of T helper cell 2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.

引用

页码：1561 / 1572

页数：12

共 50 条

[41] Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study
Kang, Da-Hyun
Kwon, Soon-Hyo
Lew, Bark-Lynn
JOURNAL OF DERMATOLOGY, 2024, 51 (03): : e63 - e65
[42] Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China
Zhu, Jiling
Wu, Hanwen
Ye, Yahui
Xu, Qiuyang
Shao, Junyi
Bai, Zicheng
Zhou, Yiwen
Li, Zhenyan
Liu, Jingjing
Li, Zhiming
DERMATITIS, 2024, 35 (06) : 636 - 645
[43] Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
Zhou, Bingjing
Peng, Cong
Li, Liqiao
Liu, Runqiu
Zhu, Lei
Chen, Xiang
Li, Jie
FRONTIERS IN MEDICINE, 2022, 9
[44] Dupilumab provides long-term efficacy over 2-5 years in adults with moderate-to-severe atopic dermatitis
Beck, L. A.
Bissonnette, R.
Wollenberg, A.
Simpson, E. L.
Thaci, D.
Praestgaard, A.
Aamodt, K.
Rossi, A. B.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E140
[45] Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center
Bai, Juan
Su, Wang
Fang, Hong
Qiao, Jianjun
AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e332 - e334
[46] Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study
Berna-Rico, Emilio
Fiz-Benito, Esther
Busto-Leis, Jose Manuel
Servera-Negre, Guillermo
de Lucas-Laguna, Raul
Feito-Rodriguez, Marta
DERMATOLOGY, 2024, 240 (02) : 337 - 342
[47] Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series
Armario-Hita, J. C.
Pereyra-Rodriguez, J.
Silvestre, J. F.
Ruiz-Villaverde, R.
Valero, A.
Izu-Belloso, R.
Jauregui-Presa, I.
Curto-Barredo, L.
Figueras-Nart, I.
Herranz-Pinto, P.
Herraez-Herrera, L.
Ortiz-de-Frutos, F. J.
Martinez-Pilar, L.
Sastre, J.
Serra-Baldrich, E.
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) : 1072 - 1074
[48] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
Blauvelt, A.
Eichenfield, L.
Sierka, D.
Chen, Z.
Khokhar, F.
Marco, A. Rodriguez
Shabbir, A.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19
[49] Treatment satisfaction with long-term dupilumab treatment in adult patients with moderate-to-severe atopic dermatitis (LIBERTY AD OLE)
Thaci, D.
Blauvelt, A.
Hussain, I
Bastian, M.
Sun, X.
Chao, J.
Levit, N. A.
Rossi, A. B.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 65 - 65
[50] Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study
Pezzolo, Elena
Schena, Donatella
Gambardella, Alessio
Rossi, Mariateresa
Barei, Francesca
Pinton, Piergiacomo Calzavara
Girolomoni, Giampiero
Naldi, Luigi
Ferrucci, Silvia Mariel
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (01) : E11 - E13

← 1 2 3 4 5 →